INNOVA CAPTAB LIMITED
INNOVACAP · General/Diversified · NSE
₹711
Current Market Price
Fair Value (DCF)
₹423
Margin of Safety
-40.5%
Updated just now
YieldIQ Score
26/100
Piotroski F-Score
4/9
Economic Moat
Moderate
Confidence
25%
ROE
—
Debt/Equity
0.33
WACC
11.1%
Market Cap
₹4,071 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.1%
Return on capital employed
EV / EBITDA
20.9×
Enterprise multiple
Debt / EBITDA
1.6×
Leverage vs earnings
Interest Coverage
77.3×
EBIT covers interest
Current Ratio
1.99×
Short-term liquidity
Asset Turnover
0.78×
Revenue per ₹ of assets
Revenue CAGR (3Y)
15.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹711.4
Bear case
₹246.11
MoS -189.1%
Base case
₹423.29
MoS -68.1%
Bull case
₹541.94
MoS -31.3%
Ratio Trends
INNOVACAP · last 4 annual periods
ROE
13.4%
ROCE
15.3%
Operating Margin
—
Debt / Equity
0.35×
PE
—
EV / EBITDA
—
Historical Financials
INNOVACAP · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹800 Cr | ₹925 Cr | ₹263 Cr | ₹1234 Cr | +15.6% |
| EBITDA | ₹98.5 Cr | ₹122 Cr | ₹167 Cr | ₹198 Cr | +26.2% |
| EBIT | — | — | ₹40.4 Cr | — | +0.0% |
| PAT | ₹64.0 Cr | ₹68.0 Cr | ₹28.7 Cr | ₹128 Cr | +26.1% |
| EPS (diluted) | — | — | ₹5.02 | — | +0.0% |
| CFO | ₹58.9 Cr | ₹67.1 Cr | ₹146 Cr | ₹63.8 Cr | +2.7% |
| CapEx | ₹-79.9 Cr | ₹-79.0 Cr | — | ₹-172 Cr | — |
| FCF | ₹-21.0 Cr | ₹-11.9 Cr | — | ₹-109 Cr | — |
| Total Assets | ₹575 Cr | ₹704 Cr | ₹1321 Cr | ₹1580 Cr | +40.0% |
| Total Debt | ₹199 Cr | ₹237 Cr | ₹34.6 Cr | ₹338 Cr | +19.3% |
| Shareholders' Equity | ₹209 Cr | ₹277 Cr | ₹831 Cr | ₹959 Cr | +66.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INNOVACAP vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SPARC SPARC | — | — | Pending | 157.9% | — |
| GUJTHEM GUJTHEM | — | — | Pending | 19.6% | — |
| AARTIDRUGS AARTI DRUGS LTD. | -29.2% | 42 | Overvalued | 12.3% | — |
| RPGLIFE RPG LIFE SCIENCES LTD | -36.4% | 50 | Overvalued | 34.5% | — |
| GUFICBIO GUFIC BIOSCIENCES LTD. | -78.9% | 35 | Overvalued | 11.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for INNOVACAP in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of INNOVACAP →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INNOVACAP →
Compare
Head-to-head with peers
Compare INNOVACAP side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INNOVACAPNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.